{"id":2240,"date":"2026-06-10T07:00:00","date_gmt":"2026-06-10T10:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2240"},"modified":"2026-06-10T07:00:00","modified_gmt":"2026-06-10T10:00:00","slug":"rss-clinica-medicina-reumatologia-ar-espondilite-lupus-anti-tnf-jak-inhibitors-dmard-biologicos","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/rss-clinica-medicina-reumatologia-ar-espondilite-lupus-anti-tnf-jak-inhibitors-dmard-biologicos\/","title":{"rendered":"RSS reumato: AR, espond, l\u00fapus, JAK, anti-TNF"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de reumatologia que reduzem RSS a descarte de seringa e gaze<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de reumatologia<\/strong> + AR artrite reumatoide ACR\/EULAR + DMARD csDMARDs MTX+leflunomida + bDMARDs anti-TNF infliximab+adalimumab+etanercept+certolizumab+golimumab + tsDMARDs JAK inhibitors tofacitinib+baricitinib+upadacitinib+filgotinib<\/strong> + espondiloartrite axial+perif\u00e9rica + AS ankylosing spondylitis + PsA + reativa + IBD-related<\/strong> + LES l\u00fapus eritematoso sist\u00eamico + nefrite l\u00fapica + s\u00edndrome antifosfol\u00edpide<\/strong> + vasculites GCA Giant Cell Arteritis + ANCA-associadas + Beh\u00e7et + Takayasu<\/strong> + esclerose sist\u00eamica + miosites + Sj\u00f6gren<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (sangue venoso FAN+anti-DNA+anti-Sm+anti-Ro+ANCA + FR Fator Reumatoide + anti-CCP + complemento C3+C4) + Grupo A2 (l\u00edquido sinovial artrocentese + bi\u00f3psia sinovial+pele+rim) + Grupo B (csDMARD MTX+leflunomida+sulfassalazina + bDMARD anti-TNF+anti-IL-6+anti-CD20+anti-IL-17+anti-IL-23 + tsDMARD JAK inhibitors + corticoide+ciclofosfamida+MMF+azatioprina Lista B\/C5) + Grupo E (perfuro pen+seringa+agulha+infus\u00e3o IV biol\u00f3gico). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para sangue venoso<\/strong> + ignoram especificidades reumatol\u00f3gicas + bDMARDs + JAK inhibitors<\/strong> + subdimensionam Lista C5 imunossupressor<\/strong> + perdem rastreabilidade biol\u00f3gico\/biossimilar<\/strong>. A realidade \u00e9 exatamente o oposto. RSS reumato opera em 5 fluxos reumatol\u00f3gicos<\/strong> \u2014 AR ACR\/EULAR (csDMARDs MTX+leflunomida + bDMARDs anti-TNF Humira+Enbrel+Remicade+Cimzia+Simponi + anti-IL-6 Actemra tocilizumab+sarilumab+anti-CD20 rituximab MabThera+anti-IL-1 anakinra+canakinumab+anti-CTLA-4 abatacept Orencia + tsDMARDs JAK Xeljanz+Olumiant+Rinvoq+Jyseleca), espondiloartrite (anti-TNF+anti-IL-17 secukinumab Cosentyx+ixekizumab Taltz+anti-IL-23 risankizumab Skyrizi+guselkumab Tremfya), LES (hidroxicloroquina+prednisona+belimumab Benlysta+anifrolumab Saphnelo IFN-\u03b1+CAR-T anti-CD19 experimental+rituximab+ciclofosfamida+MMF+voclosporin Lupkynis), vasculites (rituximab GPA\/MPA+tocilizumab GCA+avacopan Tavneos C5aR+IL-6 Beh\u00e7et+infliximab Takayasu), esclerose+miosites+Sj\u00f6gren (nintedanib Ofev SSc-ILD+tocilizumab+rituximab+IVIG+iscalimab anti-CD40).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de reumatologia, \u00e9 fundamental dimensionar RSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos reumatol\u00f3gicos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o RSS reumato tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
AR DMARDs+JAK<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nMTX+anti-TNF+JAK<\/td>\n<\/tr>\n
Espondiloartrite<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nAnti-IL-17+IL-23<\/td>\n<\/tr>\n
LES+nefrite l\u00fapica<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nHCQ+belimumab+anifrol<\/td>\n<\/tr>\n
Vasculites<\/td>\n1,5-4 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nRTX+toci+avacopan<\/td>\n<\/tr>\n
Esclerose+miosites<\/td>\n1-3 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nNintedanib+IVIG<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 10,5-31 kg\/dia<\/strong> em cl\u00ednica reumato m\u00e9dia porte.<\/p>\n

AR ACR\/EULAR + csDMARDs + bDMARDs anti-TNF + tsDMARDs JAK: o est\u00e1gio AR<\/h2>\n

A primeira camada \u00e9 AR. Padr\u00e3o setorial inclui (a) AR diagn\u00f3stico ACR\/EULAR 2010<\/strong> com escore \u22656 + articula\u00e7\u00e3o + sorologia FR Fator Reumatoide + anti-CCP + reagente fase aguda + dura\u00e7\u00e3o; (b) csDMARDs conventional synthetic 1L<\/strong> com MTX metotrexato 7,5-25mg PO\/SC weekly + leflunomida Arava 20mg\/d + sulfassalazina + hidroxicloroquina HCQ + \u00e1cido f\u00f3lico 5mg\/sem; (c) bDMARDs biol\u00f3gico 2L<\/strong> com anti-TNF infliximab Remicade J&J\/Inflectra biossimilar + adalimumab Humira AbbVie\/Hyrimoz biossimilar + etanercept Enbrel + certolizumab Cimzia UCB + golimumab Simponi Janssen + IV\/SC; (d) bDMARDs alternativos<\/strong> com anti-IL-6 tocilizumab Actemra Roche+sarilumab Kevzara Sanofi + anti-CD20 rituximab MabThera Roche + anti-IL-1 anakinra Kineret+canakinumab Ilaris + anti-CTLA-4 abatacept Orencia BMS T-cell co-stimulation; (e) tsDMARDs targeted synthetic 3L<\/strong> com JAK inhibitors tofacitinib Xeljanz Pfizer JAK1\/3+baricitinib Olumiant Lilly JAK1\/2+upadacitinib Rinvoq AbbVie JAK1+filgotinib Jyseleca Galapagos JAK1+SELECT-COMPARE+MTX comparator + boxed warning trombose+CV+malignidade.<\/p>\n

Cl\u00ednica com AR madura escala remiss\u00e3o DAS28 <2.6 60-80%<\/strong> + previne eros\u00e3o articular<\/strong> + otimiza T2T treat-to-target<\/strong>. Como discutimos no post sobre hospital especializado<\/a>, AR \u00e9 base.<\/p>\n

Espondiloartrite + LES + vasculites: o est\u00e1gio sist\u00eamico<\/h2>\n

A segunda camada \u00e9 EspA+LES+vasculite. Padr\u00e3o setorial inclui (a) espondiloartrite axial AS ankylosing spondylitis<\/strong> com BASDAI+ASDAS scores + HLA-B27+ + sacroile\u00edte radiogr\u00e1fica\/MRI + AINE 1L + anti-TNF 2L + anti-IL-17A secukinumab Cosentyx Novartis+ixekizumab Taltz Lilly + anti-IL-17A\/F bimekizumab Bimzelx UCB; (b) PsA psoriatic arthritis<\/strong> com anti-TNF + anti-IL-17 + anti-IL-23 risankizumab Skyrizi AbbVie+guselkumab Tremfya Janssen+tildrakizumab Ilumya + apremilast Otezla PDE4 + JAK inhibitor; (c) LES l\u00fapus<\/strong> com SLEDAI score + hidroxicloroquina HCQ Plaquenil 5mg\/kg\/d 1L universal + prednisona + ciclofosfamida CYC + MMF CellCept + azatioprina + belimumab Benlysta GSK anti-BAFF\/BLyS 10mg\/kg IV q4w + anifrolumab Saphnelo AstraZeneca anti-IFNAR1 IV q4w + voclosporin Lupkynis nefrite l\u00fapica + CAR-T anti-CD19 experimental Mackensen 2024; (d) vasculites ANCA-associated GPA Granulomatose Wegener+MPA Microscopic Polyangiitis+EGPA Churg-Strauss<\/strong> com rituximab Roche+ciclofosfamida CYC indu\u00e7\u00e3o + rituximab manuten\u00e7\u00e3o+azatioprina+MMF + avacopan Tavneos C5aR Pfizer ADVOCATE; (e) GCA Giant Cell Arteritis<\/strong> com prednisona alta dose + tocilizumab Actemra Roche GiACTA + Takayasu+Beh\u00e7et+IBD+anti-TNF.<\/p>\n

Cl\u00ednica com EspA+LES+vasculite madura escala remiss\u00e3o LES + previne nefrite l\u00fapica progress\u00e3o<\/strong> + escala remiss\u00e3o GCA tocilizumab<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Esclerose sist\u00eamica + miosites + Sj\u00f6gren + fibromialgia: o est\u00e1gio CTD<\/h2>\n

A terceira camada \u00e9 CTD. Padr\u00e3o setorial inclui (a) esclerose sist\u00eamica SSc<\/strong> com cut\u00e2neo difuso dcSSc+limitado lcSSc CREST + anti-Scl-70 + anticentr\u00f4mero + anti-RNA-pol-III + ILD + HAP hipertens\u00e3o arterial pulmonar + nintedanib Ofev SENSCIS + tocilizumab focuSSced + rituximab + autotransplante MO ASTIS+SCOT + iscalimab anti-CD40; (b) miosites inflamat\u00f3rias<\/strong> com PM polimiosite + DM dermatomiosite + IBM inclusion body myositis + IMNM imune-mediated necrotizing + ASS antisynthetase + anti-Jo-1+anti-Mi-2+anti-MDA5 + corticoide + IVIG + rituximab + MMF + tofacitinib + voclosporin; (c) Sj\u00f6gren<\/strong> com prim\u00e1ria + secund\u00e1ria AR\/LES + anti-Ro\/SSA + anti-La\/SSB + biopsia salivar Chisholm + xerostomia + xeroftalmia + iscalimab anti-CD40 Novartis IRIS + ianalumab anti-BAFF-R Novartis NEPTUNUS; (d) fibromialgia<\/strong> com pregabalina+gabapentina+duloxetina+milnaciprano+amitriptilina+ciclobenzaprina + low-dose naltrexona + cannabidiol + acupuntura+exerc\u00edcio+terapia cognitivo-comportamental TCC; (e) descarte CTD<\/strong> com bi\u00f3psia salivar+pele+m\u00fasculo+pulm\u00e3o + Lista B+C5 imunossupressor + IVIG IV + autotransplante MO + saco amarelo + identifica\u00e7\u00e3o Lista B\/C5+CID M30-M36+M79.7.<\/p>\n

Cl\u00ednica com SSc+miosites+Sj\u00f6gren madura escala redu\u00e7\u00e3o decl\u00ednio FVC SENSCIS<\/strong> + previne progress\u00e3o ILD\/HAP<\/strong> + escala iscalimab Sj\u00f6gren<\/strong>. Conex\u00e3o com pneumo ILD<\/a>.<\/p>\n

Tr\u00eas perfis de RSS por capacidade reumato<\/h2>\n

Cl\u00ednica reumato b\u00e1sica.<\/strong> 2 fluxos. Custo mensal R$ 12.000-32.000<\/strong> mas perda de bDMARDs+JAK+CTD.<\/p>\n

Cl\u00ednica reumato m\u00e9dia.<\/strong> 3 fluxos. Custo mensal R$ 24.000-58.000<\/strong>, captura AR+EspA+LES.<\/p>\n

Cl\u00ednica reumato completa 5 fluxos.<\/strong> AR+EspA+LES+vasculites+CTD + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 45.000-105.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura reumatol\u00f3gica + bDMARDs+JAK+belimumab+anifrolumab targeted.<\/p>\n

Os tr\u00eas erros que aparecem em reumatologia<\/h2>\n

O primeiro \u00e9 a subdimensionamento bDMARDs+JAK Lista C5<\/strong>. Sem segrega\u00e7\u00e3o anti-TNF+anti-IL-6+anti-CD20+anti-IL-17+anti-IL-23+JAK inhibitors+belimumab+anifrolumab+rituximab + Lista C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada profissional + impacto financeiro biol\u00f3gico R$ 30-150k\/ano\/paciente.<\/p>\n

O segundo \u00e9 a mistura csDMARDs+bDMARDs+tsDMARDs<\/strong>. Confunde rastreabilidade DMARD line+sequ\u00eancia + impossibilita T2T treat-to-target + risco prescri\u00e7\u00e3o inadequada AR vs EspA vs LES vs vasculite.<\/p>\n

O terceiro \u00e9 a falta de protocolo TB latente IGRA pr\u00e9-anti-TNF<\/strong>. Sem QuantiFERON-TB Gold + IGRA + screening pr\u00e9-biol\u00f3gico = risco reativa\u00e7\u00e3o TB + zero rastreabilidade biosseguran\u00e7a + viola\u00e7\u00e3o NR-32.<\/p>\n

A regula\u00e7\u00e3o de RSS reumato no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com reumatologia especializada como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBR Sociedade Brasileira Reumatologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o RSS reumato 5 fluxos completos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a AR ACR\/EULAR 2010+csDMARDs MTX+leflunomida Arava+sulfassalazina+HCQ+bDMARDs anti-TNF infliximab Remicade J&J+adalimumab Humira AbbVie+etanercept Enbrel+certolizumab Cimzia UCB+golimumab Simponi Janssen+anti-IL-6 tocilizumab Actemra Roche+sarilumab Kevzara Sanofi+anti-CD20 rituximab MabThera+anti-IL-1 anakinra Kineret+canakinumab Ilaris+anti-CTLA-4 abatacept Orencia BMS+tsDMARDs tofacitinib Xeljanz Pfizer+baricitinib Olumiant Lilly+upadacitinib Rinvoq AbbVie+filgotinib Jyseleca Galapagos+T2T DAS28+ACR\/EULAR remiss\u00e3o Lista C5, espondiloartrite AS+PsA+anti-IL-17 secukinumab Cosentyx+ixekizumab Taltz+bimekizumab Bimzelx+anti-IL-23 risankizumab Skyrizi+guselkumab Tremfya+tildrakizumab Ilumya+apremilast Otezla, LES SLEDAI+HCQ Plaquenil+belimumab Benlysta GSK anti-BAFF+anifrolumab Saphnelo AstraZeneca anti-IFNAR1+voclosporin Lupkynis+CAR-T anti-CD19 Mackensen 2024+rituximab+ciclofosfamida+MMF, vasculites ANCA GPA\/MPA\/EGPA rituximab+ciclofosfamida+avacopan Tavneos Pfizer C5aR ADVOCATE+GCA tocilizumab GiACTA+Takayasu+Beh\u00e7et+infliximab, esclerose+miosites+Sj\u00f6gren nintedanib Ofev SENSCIS+tocilizumab focuSSced+autotransplante MO ASTIS+SCOT+iscalimab anti-CD40 Novartis IRIS+ianalumab anti-BAFF-R NEPTUNUS+IVIG+rituximab+MMF.<\/p>\n","protected":false},"excerpt":{"rendered":"

RSS reumato: AR + espond + l\u00fapus + anti-TNF + JAK + DMARD. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2239,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[2563,3074,2438],"class_list":["post-2240","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-biologicos","tag-lupus","tag-reumatologia"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2240"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2240\/revisions"}],"predecessor-version":[{"id":4343,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2240\/revisions\/4343"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2239"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}